Low-dose olanzapine for levodopa induced dyskinesias

Neurology

Volumn 55, Issue 6, 2000, Pages 795-799

  Manson, A J ^a,b   Schrag, A ^a   Lees, A J ^a,b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; OLANZAPINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034718588     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.55.6.795     Document Type: Article

References (39)

1. Levodopa-induced dyskinesia: Review, observations, and speculations
2. Functional neurosurgery for Parkinson's disease has come a long way, though much remains experimental
3. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease
4. Levodopa-induced dyskinesias are improved by fluoxetine
5. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias
6. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease
7. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
8. Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias
9. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias
10. Tiapride in levodopa-induced involuntary movements
11. Treatment of involuntary movement disorders with tetrabenazine
12. Low-dose clozapine improves dyskinesias in Parkinson's disease
13. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms
14. Clozapine in elderly psychiatric patients: Tolerability, safety, and efficacy
15. Clozapine: The commitment to patient safety
16. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - A 123I IBZM single photon emission tomography (SPET) study
17. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease
18. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician
19. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes
20. Comparison of motor response to apomorphine and levodopa in Parkinson's disease
21. Worsening of levodopa-induced dyskinesias by motor and mental tasks
22. An ambulatory dyskinesia monitor
23. Utility of an objective dyskinesia rating scale for Parkinson's disease: Inter- and intrarater reliability assessment
24. Quantitative assessment of neuroleptic-induced extrapyramidal symptoms: Clinical and nonclinical approaches
25. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment
26. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease
27. Role of selective D1 and D2 agonists in inducing dyskinesia in drug- naive MPTP monkeys
28. Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys
29. Partial dopamine agonist therapy of levodopa-induced dyskinesias
30. Transdihydrolisuride in parkinsonism
31. Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum
32. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa- treated Parkinson's disease patients with and without dyskinesias
33. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
34. Olanzapine: A basic science update
35. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: A cautionary note
36. Worsening of motor features of parkinsonism with olanzapine
37. Olanzapine-induced neuroleptic malignant syndrome with mental retardation
38. Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience
39. Clozapine, a 2-year open trial in Parkinson's disease patients with psychosis